TABLE 1.
Demographic and clinical characteristics of the participants in the current studya
| Characteristic | Value for group |
P value | ||
|---|---|---|---|---|
| Total | 120–240 min postdose | 245–420 min postdose | ||
| No. of patients | 28 | 16 | 12 | |
| Mean age (yrs) ± SD (range) | 47.82 ± 17.06 (17–78) | 53.31 ± 17.00 (17–78) | 43.17 ± 16.00 (24–60) | 0.2236 |
| No. of male/no. of female patients | 16/12 | 9/7 | 7/5 | 1.0000 |
| Mean BMI ± SD (range) | 21.46 ± 3.12 (15.04–26.81) | 21.77 ± 3.07 (15.94–26.81) | 21.06 ± 3.14 (15.04–26.12) | 0.5744 |
| % (no.) of patients with site of osteoarticular TB | 0.2850 | |||
| Spinal | 85.71 (24/28) | 93.75 (15/16) | 75.00 (9/12) | |
| Site other than spine | 14.29 (4/28) | 6.25 (1/16) | 25.00 (3/12) | |
| No. of patients with prior TB infection | 3 | 2 | 1 | |
| Duration (mo) of receiving TB treatment before operation (range) | 1 (0–48) | 1 (0–48) | 0.5 (0–19) | 1.0000 |
| Mean sampling time after preoperative dose (min) ± SD (range) | 219.12 ± 73.69 (120–420) | 165.31 ± 34.35 (120–220) | 290.83 ± 45.77 (245–420) | |
| Mean dose/wt (mg · kg−1) ± SD (range) | 8.50 ± 1.39 (5.95–11.11) | 8.35 ± 1.24 (5.95–11.11) | 8.65 ± 1.57 (6.25–11.11) | 0.5963 |
| % (no.) of patients with CT finding | ||||
| Bone destruction | 100 (28/28) | 100 (16/16) | 100 (12/12) | |
| Soft-tissue swelling | 96.43 (27/28) | 100 (16/16) | 91.67 (11/12) | 0.4286 |
| Paravertebral/psoas abscess | 46.43 (13/28) | 37.50 (6/16) | 58.33 (7/12) | 0.4454 |
| Pleural thickening | 14.29 (4/30) | 12.50 (2/16) | 16.67 (2/12) | 1.0000 |
| % (no.) of patients with bacteriological examination outcome | ||||
| Culture positive | 42.86 (12/28) | 37.50 (6/16) | 50.00 (6/12) | 0.7022 |
| Xpert positive | 71.43 (20/28) | 75.00 (12/16) | 66.67 (8/12) | 0.6908 |
| RR-TB rate | 10.00 (2/20) | 8.33 (1/12) | 12.50 (1/8) | 0.5604 |
| % (no.) of patients with pathological examination outcome | ||||
| Granulomatous inflammation | 82.14 (23/28) | 81.25 (13/16) | 83.33 (10/12) | 1.0000 |
| Necrosis | 89.29 (25/28) | 93.75 (15/16) | 83.33 (10/12) | 0.5604 |
| TB molecular test positiveb | 80.77 (21/26) | 80.00 (12/15) | 81.82 (9/11) | 1.0000 |
a
BMI, body mass index; CT, computed tomography; RR-TB, rifampicin resistant-tuberculosis.
b
Molecular testing was not performed on two patients.